CN101348786A - 一种人β珠蛋白基因及其重组腺相关病毒载体 - Google Patents
一种人β珠蛋白基因及其重组腺相关病毒载体 Download PDFInfo
- Publication number
- CN101348786A CN101348786A CNA2007100440406A CN200710044040A CN101348786A CN 101348786 A CN101348786 A CN 101348786A CN A2007100440406 A CNA2007100440406 A CN A2007100440406A CN 200710044040 A CN200710044040 A CN 200710044040A CN 101348786 A CN101348786 A CN 101348786A
- Authority
- CN
- China
- Prior art keywords
- globin
- beta
- people
- viral vectors
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 title claims abstract description 27
- 239000013603 viral vector Substances 0.000 title claims description 33
- 238000001890 transfection Methods 0.000 claims abstract description 18
- 208000005980 beta thalassemia Diseases 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 11
- 108091008053 gene clusters Proteins 0.000 claims abstract description 8
- 238000001415 gene therapy Methods 0.000 claims abstract description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 80
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 43
- 239000013612 plasmid Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 10
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 230000003394 haemopoietic effect Effects 0.000 claims description 8
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 7
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 4
- 239000001506 calcium phosphate Substances 0.000 claims description 4
- 235000011010 calcium phosphates Nutrition 0.000 claims description 4
- 238000000975 co-precipitation Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000013326 plasmid cotransfection Methods 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 abstract description 14
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 abstract 1
- 208000022806 beta-thalassemia major Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 42
- 108020004414 DNA Proteins 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000000523 sample Substances 0.000 description 14
- 238000002203 pretreatment Methods 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- 108060003196 globin Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 244000309466 calf Species 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000015994 miscarriage Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241001147420 ssDNA viruses Species 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100440406A CN101348786B (zh) | 2007-07-20 | 2007-07-20 | 一种人β珠蛋白基因及其重组腺相关病毒载体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100440406A CN101348786B (zh) | 2007-07-20 | 2007-07-20 | 一种人β珠蛋白基因及其重组腺相关病毒载体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101348786A true CN101348786A (zh) | 2009-01-21 |
CN101348786B CN101348786B (zh) | 2011-05-11 |
Family
ID=40267762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100440406A Active CN101348786B (zh) | 2007-07-20 | 2007-07-20 | 一种人β珠蛋白基因及其重组腺相关病毒载体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101348786B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212556A (zh) * | 2010-04-01 | 2011-10-12 | 深圳市湘雅生物医药研究院 | 一种靶向肿瘤的双基因重组腺相关病毒载体 |
CN102925485A (zh) * | 2012-11-09 | 2013-02-13 | 中国农业科学院兰州兽医研究所 | 双表达的aav重组病毒的制备方法 |
CN106978443A (zh) * | 2017-05-04 | 2017-07-25 | 广东铱科基因科技有限公司 | 一种β‑珠蛋白重组慢病毒载体及其应用 |
CN108330147A (zh) * | 2017-01-20 | 2018-07-27 | 上海吉凯基因化学技术有限公司 | 一种重组腺相关病毒载体生产工艺的建立 |
CN109498802A (zh) * | 2013-03-15 | 2019-03-22 | 高等教育联邦系统-匹兹堡大学 | 用于治疗碳氧血红蛋白血症的组合物和方法 |
WO2019079437A1 (en) * | 2017-10-18 | 2019-04-25 | City Of Hope | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING THE FUNCTION OF THE HBB GENE AND METHODS OF USE |
CN111235158A (zh) * | 2020-03-10 | 2020-06-05 | 浙江康佰裕生物科技有限公司 | 用于表达重组人β-珠蛋白的病毒载体及其应用 |
CN113106098A (zh) * | 2021-04-21 | 2021-07-13 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
CN114395559A (zh) * | 2014-04-25 | 2022-04-26 | 吉尼松公司 | 高胆红素血症的治疗 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100408844B1 (ko) * | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
CA2451173C (en) * | 2001-06-29 | 2012-12-18 | Sloan Kettering Institute For Cancer Research | Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
-
2007
- 2007-07-20 CN CN2007100440406A patent/CN101348786B/zh active Active
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212556A (zh) * | 2010-04-01 | 2011-10-12 | 深圳市湘雅生物医药研究院 | 一种靶向肿瘤的双基因重组腺相关病毒载体 |
CN102212556B (zh) * | 2010-04-01 | 2013-12-18 | 深圳市湘雅生物医药研究院 | 一种靶向肿瘤的双基因重组腺相关病毒载体 |
CN102925485A (zh) * | 2012-11-09 | 2013-02-13 | 中国农业科学院兰州兽医研究所 | 双表达的aav重组病毒的制备方法 |
CN102925485B (zh) * | 2012-11-09 | 2014-07-09 | 中国农业科学院兰州兽医研究所 | 双表达的aav重组病毒的制备方法 |
CN109498802A (zh) * | 2013-03-15 | 2019-03-22 | 高等教育联邦系统-匹兹堡大学 | 用于治疗碳氧血红蛋白血症的组合物和方法 |
CN109498802B (zh) * | 2013-03-15 | 2021-11-09 | 高等教育联邦系统-匹兹堡大学 | 用于治疗碳氧血红蛋白血症的组合物和方法 |
CN114395559A (zh) * | 2014-04-25 | 2022-04-26 | 吉尼松公司 | 高胆红素血症的治疗 |
CN108330147A (zh) * | 2017-01-20 | 2018-07-27 | 上海吉凯基因化学技术有限公司 | 一种重组腺相关病毒载体生产工艺的建立 |
CN106978443A (zh) * | 2017-05-04 | 2017-07-25 | 广东铱科基因科技有限公司 | 一种β‑珠蛋白重组慢病毒载体及其应用 |
CN106978443B (zh) * | 2017-05-04 | 2020-01-14 | 济南赛尔生物科技股份有限公司 | 一种β-珠蛋白重组慢病毒载体及其应用 |
WO2019079437A1 (en) * | 2017-10-18 | 2019-04-25 | City Of Hope | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING THE FUNCTION OF THE HBB GENE AND METHODS OF USE |
CN111447954A (zh) * | 2017-10-18 | 2020-07-24 | 希望之城 | 用于恢复hbb基因功能的腺相关病毒组合物及其使用方法 |
CN111235158A (zh) * | 2020-03-10 | 2020-06-05 | 浙江康佰裕生物科技有限公司 | 用于表达重组人β-珠蛋白的病毒载体及其应用 |
CN113106098A (zh) * | 2021-04-21 | 2021-07-13 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101348786B (zh) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101348786B (zh) | 一种人β珠蛋白基因及其重组腺相关病毒载体 | |
US20190351073A1 (en) | Factor viii mutation repair and tolerance induction | |
Ratajczak et al. | Acute-and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides | |
WO2019178426A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
CN101511373A (zh) | 用于基因治疗的修饰的因子viii和因子ix基因和载体 | |
WO2018170184A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
EP3155098A1 (en) | FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION AND RELATED CDNAs, COMPOSITIONS, METHODS AND SYSTEMS | |
CN104937100A (zh) | Aav变体 | |
CN108977452A (zh) | 优化的人凝血因子ix基因表达盒及其应用 | |
US20220073951A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
JP2022530126A (ja) | 新規アデノ随伴ウイルス(aav)バリアント及び遺伝子治療のためのその使用 | |
WO2023160317A1 (zh) | 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用 | |
WO2019094518A1 (en) | Targeted integration systems and methods for the treatment of hemoglobinopathies | |
US20220047637A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
CN109337928A (zh) | 通过过表达腺相关病毒受体提高基因治疗效率的方法 | |
CN112175064B (zh) | Kgf蛋白外泌体的制备方法、kgf蛋白外泌体干粉、应用及一种毛发护理剂 | |
JP2020517289A (ja) | Hla遺伝子のrnaガイドゲノム編集を使用して関節リウマチを処置する方法 | |
Nienhuis et al. | Gene transfer into hematopoietic cells | |
US20220025363A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
CN115948403B (zh) | 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用 | |
CN112695032B (zh) | 一种启动子pLRRK2及其应用 | |
CN105012969A (zh) | 一种保护和促进斑秃处毛发再生的药物及其应用 | |
US20230136849A1 (en) | Capsid-modified raav vector compositions and methods therefor | |
WO2023014727A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
CN114107214A (zh) | 一种通用型异体car-t细胞制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN ZHENXING GENE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: TAN MENGQUN Effective date: 20140327 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410078 CHANGSHA, HUNAN PROVINCE TO: 518048 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140327 Address after: Three road 518048 Guangdong city of Shenzhen province Futian District Yitian road and Fuhua junction center of northeast Shenzhen International Chamber of Commerce 3803A1 Patentee after: Shenzhen Xing Xing Gene Technology Co., Ltd. Address before: 410078 Hunan province Changsha Xiangya Road No. 110, No. 24. Patentee before: Tan Mengqun |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160405 Address after: 518057 Guangdong province Shenzhen city Nanshan District high technology district two Road No. 39 building seven floor Wanji Pharmaceutical Research Park Patentee after: Shenzhen Xiangya Biological Medical Institute Address before: Three road 518048 Guangdong city of Shenzhen province Futian District Yitian road and Fuhua junction center of northeast Shenzhen International Chamber of Commerce 3803A1 Patentee before: Shenzhen Xing Xing Gene Technology Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180917 Address after: 518000 Room 201, building A, 1 front Bay Road, Shenzhen Qianhai cooperation zone, Shenzhen, Guangdong Patentee after: Shenzhen Zhenxing Medicine Technology Co., Ltd. Address before: 518057 seven floor, research building, 39 Wan Ji pharmaceutical Park, 39 science and technology middle two road, Nanshan District high tech center, Guangdong, China Patentee before: Shenzhen Xiangya Biological Medical Institute |
|
TR01 | Transfer of patent right |